PA
ESPR

Procyon Advisors’s Esperion Therapeutics ESPR Stock Holding History

Procyon Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,000
Closed -$223K – 236
2020
Q3 		$223K Hold
6,000
– – 0.12% 183
2020
Q2 		$308K Hold
6,000
– – 0.16% 127
2020
Q1 		$189K Buy
6,000
+1,500
+33% +$79.2K 0.13% 158
2019
Q4 		$268K Buy
+4,500
New +$202K 0.16% 128

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Procyon Advisors's ESPR Position: Q4 2020 in Review

Procyon Advisors sold out of Esperion Therapeutics (ESPR) in Q4 2020, closing a stake of 6,000 shares — an estimated $223K sold.

Procyon Advisors first reported a position in ESPR in Q4 2019 and held it in 4 quarters. The position peaked at $308K in Q2 2020. 157 funds tracked by Wall St. Rank hold ESPR as of Q4 2020.

  • Procyon Advisors reported no remaining Esperion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Procyon Advisors sold 6,000 Esperion Therapeutics shares in Q4 2020, an estimated $223K.
  • Procyon Advisors first reported a position in Esperion Therapeutics in Q4 2019 and held it in 4 quarters.
  • Procyon Advisors's Esperion Therapeutics position peaked at $308K in Q2 2020.
  • 157 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2020.

Based on Procyon Advisors's 13F filing for Q4 2020, filed 19 Jan 2021.